ADC Therapeutics's major customers
AmerisourceBergen accounted for 39% of ADC Therapeutics's revenue in FY 2025, about the same as 35% a year earlier.
Get an email when ADC Therapeutics's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of ADC Therapeutics
Customers that ADC Therapeutics named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| AmerisourceBergen | 39% | from 35% | 4 years | FY 2025 · filed 10 Mar 2026 |
| McKessonMCK | 39% | from 41% | 4 years | FY 2025 · filed 10 Mar 2026 |
| Cardinal HealthCAH | 22% | from 24% | 4 years | FY 2025 · filed 10 Mar 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API